Short Interest in Gain Therapeutics, Inc. (NASDAQ:GANX) Expands By 64.5%

Gain Therapeutics, Inc. (NASDAQ:GANX) was the recipient of a significant growth in short interest in the month of December. As of December 15th, there was short interest totaling 2,073,310 shares, a growth of 64.5% from the November 30th total of 1,260,732 shares. Currently, 5.8% of the shares of the company are sold short. Based on an average daily volume of 1,377,957 shares, the days-to-cover ratio is currently 1.5 days. Based on an average daily volume of 1,377,957 shares, the days-to-cover ratio is currently 1.5 days. Currently, 5.8% of the shares of the company are sold short.

Gain Therapeutics Price Performance

GANX traded down $0.07 during midday trading on Friday, reaching $3.15. 576,275 shares of the company’s stock were exchanged, compared to its average volume of 2,177,527. The company has a quick ratio of 2.52, a current ratio of 2.52 and a debt-to-equity ratio of 0.05. The business has a 50-day simple moving average of $2.84 and a two-hundred day simple moving average of $2.13. The firm has a market capitalization of $121.16 million, a price-to-earnings ratio of -5.16 and a beta of 0.06. Gain Therapeutics has a one year low of $1.41 and a one year high of $4.34.

Gain Therapeutics (NASDAQ:GANX) last issued its earnings results on Wednesday, November 12th. The company reported ($0.15) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.15). As a group, research analysts predict that Gain Therapeutics will post -1 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of GANX. Marshall Wace LLP raised its holdings in Gain Therapeutics by 41.0% in the second quarter. Marshall Wace LLP now owns 276,433 shares of the company’s stock worth $498,000 after purchasing an additional 80,407 shares during the period. Squarepoint Ops LLC acquired a new position in shares of Gain Therapeutics in the 3rd quarter valued at $68,000. Virtu Financial LLC increased its position in shares of Gain Therapeutics by 126.9% in the 3rd quarter. Virtu Financial LLC now owns 54,008 shares of the company’s stock valued at $96,000 after buying an additional 30,207 shares in the last quarter. JPMorgan Chase & Co. acquired a new stake in Gain Therapeutics during the 3rd quarter worth $47,000. Finally, Wealth Enhancement Advisory Services LLC bought a new position in Gain Therapeutics during the third quarter worth about $28,000. Institutional investors and hedge funds own 11.97% of the company’s stock.

Analyst Upgrades and Downgrades

GANX has been the subject of a number of analyst reports. Maxim Group boosted their price objective on shares of Gain Therapeutics from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Tuesday, October 7th. Roth Capital reiterated a “buy” rating and issued a $10.00 target price on shares of Gain Therapeutics in a report on Friday, December 19th. Weiss Ratings reissued a “sell (e+)” rating on shares of Gain Therapeutics in a research report on Monday, December 22nd. BTIG Research reaffirmed a “buy” rating and issued a $9.00 price target on shares of Gain Therapeutics in a research report on Wednesday, October 15th. Finally, HC Wainwright reiterated a “buy” rating and issued a $8.00 price objective on shares of Gain Therapeutics in a research note on Friday, December 19th. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $8.67.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.